Asset / Drug

TALZENNA

Drug and asset intelligence for TALZENNA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Pfizer →

Recent signals(1)

ClinicalJune 16, 2026

TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer

The Phase 3 TALAPRO-3 study demonstrated that TALZENNA plus XTANDI significantly improved radiographic progression-free survival (rPFS) by 52% in patients with HRR gene-altered metastatic prostate cancer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Pfizer — TALZENNA

Monitor for regulatory submissions and potential label expansions for TALZENNA and XTANDI based on these trial results.

June 16, 2026 · N/A

Indications

Prostate Cancer →

Therapeutic areas

Oncology →

Oncology · Prostate Cancer →

Prostate Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.